View in EDS HTML Full Text PDF Full Text

Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on "Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29 , 9891–9895"

Saved in:
Bibliographic Details
Title: Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on "Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29 , 9891–9895"
Authors: Rayson, Daniel1 (AUTHOR) daniel.rayson@nshealth.ca, Gandhi, Sonal2 (AUTHOR), Joy, Anil A.3 (AUTHOR), Brezden-Masley, Christine4 (AUTHOR), Gelmon, Karen A.5 (AUTHOR), Sehdev, Sandeep6 (AUTHOR), Cescon, David7 (AUTHOR), Chia, Stephen5 (AUTHOR)
Source: Current Oncology. May2023, Vol. 30 Issue 5, p5050-5053. 4p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:11980052
DOI:10.3390/curroncol30050381